Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study

Objectives. To determine the feasibility of comparing the Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus treatment plans (CTP) in treating moderate new-onset juvenile dermatomyositis ( JDM) using the CARRA registry, and to establish appropriate analytic methods to control for confounding by indication and missing data. Methods. A pilot cohort of 39 patients with JDM from the CARRA registry was studied. Patients were assigned by the treating physician, considering patient/family preferences, to 1 of 3 CTP: methotrexate (MTX) and prednisone (MP); intravenous (IV) methylprednisolone, MTX, and prednisone (MMP); or IV methylprednisolone, MTX, prednisone, and IV immunoglobulin (MMPI). The primary outcome was the proportion of patients achieving moderate improvement at 6 months under each CTP. Statistical methods including multiple imputation and inverse probability of treatment weighting were used to handle missing data and confounding by indication. Results. Patients received MP (n = 13), MMP (n = 18) and MMPI (n = 8). Patients in all CTP had significant improvement in disease activity. Of the 36 patients who remained in our pilot study at 6 months, 16 (44%) of them successfully achieved moderate improvement at 6 months (6/13, 46% for MP; 7/15, 47% for MMP; 3/8, 38% for MMPI). After correcting for confounding, there were no statistically significant pair-wise differences between the CTP (P = 0.328-0.88). Conclusion. We gained valuable experience and insight from our pilot study that can be used to guide the design and analysis of comparative effectiveness studies using the CARRA registry CTP approach. Our analytical methods can be adopted for future comparative effectiveness studies and applied to other rare disease observational studies.

Automated summary

The study aimed to assess the feasibility of using CARRA registry for treating JDM with CTP and establish appropriate analytical methods. Results showed significant improvement in disease activity for patients under different treatment plans. 44% of patients achieved moderate improvement at 6 months, and there were no statistically significant differences between the CTPs after correction for confounding.